Nailing down another deal with its Tumor-Activated Prodrug (TAP) technology, ImmunoGen Inc. is getting $1 million up front and as much as $42 million in milestone payments from Biogen Idec Inc., which is researching antibodies to an undisclosed tumor-cell target. (BioWorld Today)

Almost exactly a year after AstraZeneca plc quit its deal with NicOx SA for COX-inhibiting nitric oxide-donating (CINOD) drugs, NicOx said it expects to net about €24 million (US$29.8 million) through a private placement that will be used mainly to advance a lead compound from that program. (BioWorld International)

On the heels of raising $44 million in a Series C Round, MediciNova Inc. filed with the SEC to raise $100 million in an initial public offering in Japan, where it was founded four years ago as a subsidiary of Tanabe Seiyaku Co. Ltd., of Osaka. (BioWorld Today)

A bit of you know what at the end of the tunnel came for Miravant Medical Technologies Inc. in the form of an approvable letter for its light-activated drug to treat age-related macular degeneration, although the FDA is asking for another confirmatory trial. (BioWorld Today)